Management of an acute exacerbation of COPD: Are we ignoring the evidence?

Thorax

Volumn 57, Issue SUPPL. 2, 2002, Pages

  Johnson, M K ^a   Stevenson, R D ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; IPRATROPIUM BROMIDE; METHYLPREDNISOLONE; METHYLXANTHINE; MUCOLYTIC AGENT; ORCIPRENALINE; PREDNISOLONE; SALBUTAMOL;

ASSISTED VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; MEDICAL ASSESSMENT; MORTALITY; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VACCINATION;

ACUTE DISEASE; AGED; ANTIOXIDANTS; BRONCHODILATOR AGENTS; DOXAPRAM; EXPECTORANTS; GLUCOCORTICOIDS; HUMANS; INFLUENZA VACCINES; MIDDLE AGED; PHYSICAL THERAPY MODALITIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION, ARTIFICIAL; RESPIRATORY SYSTEM AGENTS;

EID: 17144434055     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Roberts CM, Ryland I, Lowe D, et al on behalf of the Audit Subcommittee of the Standards of Care Committee of the British Thoracic Society and the Clinical Effectiveness and Evaluation Unit at the Royal College of Physicians. Audit of acute admissions of COPD: standards of care and management in the hospital setting. Eur Respir J 2000;17:343-9.
2. COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(Suppl 5):S1-28.
3. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789-94.
4. Department of Health. Hospital in-patient data based on hospital episode statistics 2000/01. www.doh.gov.uk/hes, 2001.
5. Guest JF. The annual cost of chronic obstructive pulmonary disease to the UK's National Health Service. Dis Manage Health Outcomes 1999;5:93-100.
6. Department of Health. Hospital in-patient data based on hospital episode statistics 1992/93. London: HMSO, 1993.
7. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
8. Peach H, Pathy MS. Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis. Thorax 1981;36:585-9.
9. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
10. Roberts CM, Lowe D, Bucknall CE, et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002;57:137-41.
11. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-67.
12. Gibson PG, Wlodarczyk JH, Wilson AJ, et al. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J Qual Clin Pract 1998;18:125-33.
13. Mushlin AI, Black ER, Connolly CA, et al. The necessary length of hospital stay for chronic pulmonary disease. JAMA 1991;266:80-3.
14. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852-7.
15. Breen D, Churches T, Hawker F, et al. Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study. Thorax 2002;57:29-33.
16. Schwartz J. Air pollution and hospital admissions for the elderly in Detroit, Michigan. Am J Respir Crit Care Med 1994;150:648-55.
17. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646-52.
18. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20.
19. Gompertz S, Bayley DL, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36-41.
20. Derenne JP, Whitelaw WA, Similowski T, Acute respiratory failure in chronic obstructive pulmonary disease. Lung Biology in Health and Disease. Volume 92. New York: Marcel Dekker, 1996.
21. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(5 Suppl 2):398-401S.
22. Holleman DR, Simel DL, Goldberg JS. Diagnosis of obstructive airways disease from the clinical examination. J Gen Intern Med 1993;8:63-8.
23. Holleman DR, Simel DL. Does the clinical examination predict airflow limitation? JAMA 1995;273:313-9.
24. Plant PK, Owen JL, Elliott MW. One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. Thorax 2000;55:550-4.
25. Emerman CL, Cydulka RK. Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1993;22:680-4.
26. Tsai TW, Gallagher EJ, Lombardi G, et al. Guidelines for the selective ordering of admission chest radiography in adult obstructive airway disease. Ann Emerg Med 1993;22:1854-8.
27. Brown CD, McCrory DC, White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. In: Cochrane Database of Systematic Reviews. Oxford: Update Software, 2002.
28. Backman R, Hellstrom P-E. Femoterol and ipratropium bromide in respiratory treatment of patients with chronic bronchitis. Curr Ther Res 1985;38:135-40.
29. Karpel JP, Pesin J, Greenberg D, et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98:835-9.
30. Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987;82:59-64.
31. Moayyedi P, Congleton J, Page RL, et al. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995;50:834-7.
32. Patrick DM, Dales RE, Stark RM, et al. Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. Chest 1990;98:295-7.
33. O'Driscoll BR, Taylor RJ, Horsley MG, et al. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989;1:1418-20.
34. Shrestha M, O'Brien T, Haddox R, et al. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to beta-agonist therapy. Ann Emerg Med 1991;20:1206-9.
35. Turner MO, Patel A, Ginsburg S, et al. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 1997;157:1736-44.
36. Barr RG, Rowe BH, Camargo CA Jr. Methyl-xanthines for exacerbations of chronic obstructive pulmonary disease. In: Cochrane Database of Systematic Reviews. Oxford: Update Software, 2000.
37. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000;117(2 Suppl):42-7S.
38. Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
39. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456-60.
40. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Erigi J Med 1999;340:1941-7.
41. McEvoy CE, Niewoehner DE. Corticosteroids in chronic obstructive pulmonary disease. Clinical benefits and risks. Clin Chest Med 2000;21:739-52.
42. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997;111:732-43.
43. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
44. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45.
45. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116:40-6.
46. Seemungal TA, Harper-Owen R, Bhowmik A, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000;16:677-83.
47. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-60.
48. Pines A, Raafat H, Plucinski K, et al. Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis. BMJ 1968;2:735-8.
49. Sachs AP, Koeter GH, Groenier KH, et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995;50:758-63.
50. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
51. Swinburn CR, Mould H, Stone TN, et al. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis 1991;143:913-5.
52. Bone RC, Pierce AK, Johnson RL Jr. Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease: a reappraisal. Am J Med 1978;65:896-902.
53. Bedon GA, Block AJ, Ball WC. The "28 percent" Venturi mask in obstructive airway disease. Arch Intern Med 1970;125:106-13.
54. Eldridge F, Gherman C. Studies of oxygen administration in respiratory failure. Ann Intern Med 1968;68:569-78.
55. Warrell DA, Edwards RH, Godfrey S, et al. Effect of controlled oxygen therapy on arterial blood gases in acute respiratory failure. BMJ 1970;1:452-5.
56. Dunn WF, Nelson SB, Hubmayr RD. Oxygen-induced hypercarbia in obstructive pulmonary disease. Am Rev Respir Dis 1991;144:526-30.
57. Jeffrey AA, Warren PM, Flenley DC. Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management. Thorax 1992;47:34-40.
58. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333:817-22.
59. Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995;151:1799-806.
60. Martin TJ, Hovis JD, Costantino JP, et al. A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure. Am J Respir Crit Care Med 2000;161:807-13.
61. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000;355:1931-5.
62. Wysocki M, Tric L, Wolff MA, et al. Noninvasive pressure support ventilation in patients with acute respiratory failure. Chest 1993;103:907-13.
63. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993;341:1555-7.
64. Plant PK, Owen JL, Elliott MW. Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome. Thorax 2001;56:708-12.
65. Soo Hoo GW, Santiago S, Williams AJ. Nasal mechanical ventilation for hypercapnic respiratory failure in chronic obstructive pulmonary disease: determinants of success and failure. Crit Care Med 1994;22:1253-61.
66. Ambrosino N, Foglio K, Rubini F, et al. Non-invasive mechanical ventilation in acute respiratory failure due to chronic obstructive pulmonary disease: correlates for success. Thorax 1995;50:755-7.
67. Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999;160:1585-91.
68. Costello R, Deegan P, Fitzpatrick M, et al. Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis. Am J Med 1997;102:239-44.
69. NHLBI/WHO. Global initiative for chronic obstructive lung disease. NHLBI/WHO Workshop Report, 2001.
70. Nava S, Ambrosino N, Clini E, et al. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial. Ann Intern Med 1998;128:721-8.
71. Girault C, Daudenthun I, Chevron V, et al. Noninvasive ventilation as a systematic extubation and weaning technique in acute-on-chronic respiratory failure: a prospective, randomized controlled study. Am J Respir Crit Care Med 1999;160:86-92.
72. Gust R, Gottschalk A, Schmidt H, et al. Effects of continuous (CPAP) and bi-level positive airway pressure (BiPAP) on extravascular lung water after extubation of the trachea in patients following coronary artery bypass grafting. Intens Care Med 1996;22:1345-50.
73. Jiang JS, Kao SJ, Wang SN. Effect of early application of biphasic positive airway pressure on the outcome of extubation in ventilator weaning. Respirology 1999;4:161-5.
74. Edwards G, Leszczynski SO. A double-blind trial of five respiratory stimulants in patients in acute ventilatory failure. Lancet 1967;226-9.
75. Moser KM, Luchsinger PC, Adamson JS, et al. Respiratory stimulation with intravenous doxapram in respiratory failure. A double-blind co-operative study. N Engl J Metd 1973;288:427-31.
76. Angus RM, Ahmed AA, Fenwick LJ, et al. Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease. Thorax 1996;51:1048-50.
77. Greenstone M. Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. In: Cochrane Database of Systematic Reviews. Oxford: Update Software, 1997.
78. Petersen ES, Esmann V, Honcke P, et al. A controlled study of the effect of treatment on chronic bronchitis. An evaluation using pulmonary function tests. Acta Med Scand 1967;182:293-305.
79. Langlands JH. Double-blind clinical trial of bromhexine as a mucolytic drug in chronic bronchitis. Lancet 1970;1:448-50.
80. Peralta J, Poderoso JJ, Corazza C, et al. Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis. Arzneimittel-Forschung 1987;37:969-71.
81. Aylward M. A between-patient, double-blind comparison of S-carboxymethylcysteine and bromhexine in chronic obstructive bronchitis. Curr Med Res Opin 1973;1:219-27.
82. Finiguerra M, Conti P, Figura I. Clinical study of the effects of an antibiotic and mucolytic association (amoxycillin and domiodol) in hypersecretory chronic bronchopulmonary diseases. Curr Ther Res 1982;31:895-905.
83. Newton DA, Stephenson A. Effect of physiotherapy on pulmonary function. A laboratory study. Lancet 1978;ii:228-9.
84. Wollmer P, Ursing K, Midgren B, et al. Inefficiency of chest percussion in the physical therapy of chronic bronchitis. Eur J Respir Dis 1985;66:233-9.
85. Gravil JH, Al Rawas OA, Cotton MM, et al. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. Lancet 1998;351:1853-5.
86. Cotton MM, Bucknall CE, Dagg KD, et al. Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Thorax 2000;55:902-6.
87. Skwarska E, Cohen G, Skwarski KM, et al. Randomized controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax 2000;55:907-12.
88. Davies L, Wilkinson M, Bonner S, et al. "Hospital at home" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. BMJ 2000;321:1265-8.
89. Johnson MK, Choo-Kang BSW, Sarvesvaran JS, et al. Growth in hospital at home services for acute exacerbation of chronic obstructive pulmonary disease. Thorax 2001;56(Suppl III):iii11.
90. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-64.
91. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-8.
92. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161:381-90.
93. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;i:681-6.
94. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8.
95. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
96. Spencer S, Calverley PM, Sherwood BP, et al, ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-8.
97. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351:773-80.
98. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-4.
99. Weir DC, Bale GA, Bright P, et al. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin Exp Allergy 1999;29(Suppl 2):125-8.
100. van Grunsven PM, van Schayck CP, Derenne JP, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;64:7-14.
101. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med 1999;340:1948-53.
102. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
103. Friedman M, Serby CW, Menioge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115:635-41.
104. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
105. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
106. Vincken W, Van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002;19:209-16.
107. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001;322:1271-4.
108. Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000;16:253-62.
109. Poole PJ, Chacko E, Wood-Baker RW, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. In: Cochrane Database of Systematic Reviews. Issue 4. Oxford: Update Software, 2000: CD002733.
110. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-27.
111. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77.
112. Koivula I, Sten M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103:281-90.
113. Nichol KL, Baken L, Wuorenma J, et al. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437-42.
114. Foglio K, Bianchi L, Bruletti G, et al. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J 1999;13:125-32.
115. Stewart DG, Drake DF, Robertson C, et al. Benefits of an inpatient pulmonary rehabilitation program: a prospective analysis. Arch Phys Med Rehabil 2001;82:347-52.
116. Young P, Dewse M, Fergusson W, et al. Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable to a hospital-based respiratory rehabilitation programme. Aust NZ J Med 1999;29:59-65.
117. Bowen JB, Thrall RS, ZuWallack RL, et al. Long-term benefits of short-stay inpatient pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1999;54:189-92.
118. Guell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest 2000;117:976-83.
119. Griffiths TL, Burr ML, Campbell lA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000;355:362-8.
120. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000;117(2 Suppl):10-4S.